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This editorial refers to ‘Dynamic relationship of left-
ventricular dyssynchrony and contractile reserve in
patients undergoing cardiac resynchronization therapy’†,
by I. Stankovic et al., on page 48–55
The challenge of non-response to
cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT) is a cornerstone of
modern day heart failure therapy due to the consistent reduction
in morbidity and mortality observed in large-scale clinical trials in
patients with a severely reduced left ventricular ejection fraction
(LVEF ≤35%), symptomatic heart failure, and a wide QRS
complex.1– 5 The individual benefit derived from CRT, however,
may vary considerably, with a significant number of subjects demon-
strating good or even excellent clinical and echocardiographic
improvement and others showing little to no response.6 A reliable
a priori identification of these so-called non-responders represents
one of the most important challenges for physicians involved in the
care of these patients. Some electrocardiographic as well as clinical
parameters have so far been identified as being associated with an
increased likelihood for response to CRT, including a very wide
QRS complex (≥150 ms), left bundle branch block morphology of
the QRS complex, lack of ischaemic cardiomyopathy, and female
gender.1,4,6,7 However, so far, no single parameter has been found
to be robust enough to exclude a priori otherwise eligible patients
from receiving a CRT device. As a result, other methods including
echocardiographic assessment of ventricular dyssynchrony were
probed to identify these patients as well as, conversely, individuals
likely to respond to CRT.
Mechanical dyssynchrony and
cardiac resynchronization therapy
in narrow QRS: Paradise Lost
As the majority of heart failure patients do not present with a QRS
width ≥120 ms,8 it intuitively appeared reasonable to investigate
whether echocardiographic parameters of dyssynchrony would be
able to identify subjects with narrow QRS likely to derive a benefit
from CRT. Indeed, various small studies were able to identify patients
who demonstrated a substantial echocardiographic and clinical
improvement following CRT.6,9,10
Following these single-centre preliminary studies, however, two
small-scale randomized clinical trials showed conflicting results
regarding the usefulness of echocardiographic parameters in the se-
lection of CRT candidates with narrow QRS complex. In the recently
published single-blind NARROW-CRT trial, 117 patients with ven-
tricular dyssynchrony on tissue Doppler imaging were randomized
to either CRT-D or ICD (implantable cadioverter defibrillator) im-
plantation.11 The heart failure clinical composite response (primary
study endpoint) improved more frequently in CRT-D than ICD reci-
pients; furthermore, the composite of heart failure hospitalization,
cardiovascular death, and spontaneous ventricular fibrillation oc-
curred less frequently in CRT-D patients. In a similar setting, the ran-
domized Cardiac Resynchronization Therapy in Patients with Heart
Failure and Narrow QRS (RethinQ) study previously investigated the
effect of CRT in 172 patients with a narrow QRS (≤130 ms) and
echocardiographic signs of mechanical dyssynchrony as assessed by
tissue Doppler imaging.12 However, contrary to the other studies
mentioned above, the primary endpoint (increase in peak oxygen
consumption ≥1 mL/kg during cardiopulmonary exercise testing)
occurred to a similar degree in both groups.
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Several weaknesses are inherent to both studies, including the low
number of patients, a short follow-up period, and, consequently, lack
of statistical power for hard clinical endpoints. The recently pre-
sented EchoCRTtrial was designed to overcome these shortcomings
by evaluating the effect of CRT on morbidity and mortality in patients
with a narrow QRS complex ( ≤ 130 ms) and echocardiographic
signs of ventricular dyssynchrony in a large randomized double-blind
event-driven clinical trial (presented at ESC 2013). The trial was re-
cently terminated early due to futility of CRT in this patient popula-
tion. Together with the aforementioned studies, one of the most
likely although counter-intuitive conclusions may be that correction
of mechanical dyssynchrony without electrical dyssynchronymay not
be the therapeutic principle behind CRT.
Mechanical dyssynchrony and
cardiac resynchronization therapy
in wide QRS: more questions than
answers
A similar, albeit not as gloomysituation canbe encountered regarding
the role of dyssynchrony parameters in the (sub-) selection of CRT
patients with a wide QRS complex. After various positive small-scale
studies had raised considerable hope, the largest prospective
multicentre trial (PROSPECT)was unable to finda singleechocardio-
graphic measure of dyssynchrony through which patient selection for
CRT could be improved.13 The PROSPECT study enrolled 498 heart
failure patients from 53 centres, who fulfilled standard CRT indica-
tions (NYHA functional class III or IV, LVEF ≤35%, QRS ≥130 ms).
After 6 months of CRT, the clinical composite score improved in
69% of 426 patients, and LV end-systolic volume was reduced
by ≥15% in 56% of 286 patients. The investigated 12 (!) echocardio-
graphic parameters, however, demonstrated large variations for the
prediction of clinical outcomes (6–74% and 35–91% for sensitivity
and specificity, respectively) or reduction in LV end-systolic volume
response (9–77% and 31–93%, respectively). Admittedly, the
PROSPECT trial has been criticized on several fronts, including the
high interobserver variability in echocardiographic assessment, inad-
equate echocardiographic training, outdated equipment, short
follow-up, and residual confounding. Nevertheless, with the only
prospective trial being negative, strong evidence for the usefulness
of echocardiography for patient selection in CRT is still lacking.
Apical rocking in severely reduced
ejection fraction and wide QRS:
another marker for mechanical
dyssynchrony
Stankovic et al.14 have used apical rocking (ApRock) as a surrogate
marker for LV dyssynchrony in patients with wide QRS, which was
quantified by measuring the apical transverse motion (ATM), i.e.
the motion of the LV apex perpendicular to the LV long axis, in
the apical four-chamber view. In their cohort, they prospectively
Figure1 Mechanical dyssynchrony occurs secondary to electrical dyssynchrony [left bundle branch block (LBBB)], which is corrected by cardiac
resynchronization therapy. Colours indicate areas of early (red) to late (blue) activation of the ventricles.
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enrolled 58 CRT candidates according to current guidelines
and assessed ApRock as well as LVEF at baseline and during
low-dose dobutamine stress echocardiography (DSE). An increase
in ApRock during DSE was associated with a pronounced response
to CRT (as defined by a decrease in end-systolic volume .10%),
but correlated inversely with an improvement in EF after CRT
(i.e. the more pronounced the ApRock the less likely was an
improvement in EF). Furthermore, and more importantly, a
DSE-induced increase in ApRock (but not LVEF) was associated
with improved long-term survival during a mean follow-up of 41+
13 months after CRT implantation.
The authors are to be congratulated for the careful conduct of
their study as well as the meticulous echocardiographic analyses.
Bydoing so, theywereable todemonstrate that an increase in dyssyn-
chrony (as assessed by ApRock), but not in LVEF during DSE may
predict response to CRT and survival. Mechanistically, this is
equally of interest, as it implies that patients with an increase in myo-
cardial contractile reserve resulting in moredyssynchrony may derive
a greaterbenefit fromCRT, whereas an increase in LVEF during stress
appears to be of lesser value. Differences from similar studies, which
did find a positive influence of LVEF augmentation during DSE, may
well be, as acknowledged by the authors, due to different definitions
of dyssynchrony as well as different definitions of outcome and echo-
cardiographic ‘response’.
Implications for daily clinical
practice
Despite the well presented data and the convincing results, the ultim-
ate question for clinicians involved in the care of heart failure patients
will be: how far do the results of the study of Stankovic et al. alter the
way we will select patients for CRT? Indeed, certain parallels with the
aforementioned hypothesis of CRT in narrow QRS with ventricular
dyssynchrony cannot be neglected, with this study equally being
rather small scale, single centre, and observational in nature. The im-
portance of the results, as clear and intuitive as theymayseem, should
hence not be overestimated but should be regarded as ‘hypothesis-
generating’ at best.
Will patients with an absence of ApRock at baseline or during DSE
be denied a CRT device, even if they otherwise fulfil current guide-
lines? Conversely, should a CRT device be implanted in patients
justbasedon ApRockwhootherwisewould not qualify? Inboth scen-
arios, the answer at this point in time clearly is: no. Indeed, the host of
positive data from large-scale landmark trials justifies CRT implant-
ation in patients meeting current guideline criteria, irrespective of
echocardiographically measured dyssynchrony. Even more import-
antly, however, CRT implantation cannot be recommended in
patients who otherwise do not qualify for it, e.g. patients with pre-
served EF or narrow QRS complex, just based on positive ApRock
on echocardiography. Observational data from the past have indi-
cated that it may indeed be possible not only to have a neutral
effect with CRT, but that one may in fact induce harm by biventricular
stimulation in certain patients. The latter has just been confirmed
with the highest level of evidence, i.e. in the context of the
EchoCRT study. These findings impressively demonstrate how a
beautiful hypothesis, i.e. a beneficial effect of resynchronization in
mechanically dyssynchronous hearts, can be proven wrong by ugly
facts. Whether the same is true for ApRock and in which setting, of
course, cannot be determined at this point in time. To evaluate
this, confirmation in a large-scale randomized trial powered for
hard clinical outcome parameters of morbidity and mortality is indis-
pensable, possibly in the sense of a ‘PROSPECT-2’ trial. The unex-
pected experience from EchoCRT serves as a clear and present
reminder that this highest level of evidence is necessary and needs
to be awaited before altering clinical practice according to newly
defined selection criteria for CRT.
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